Trials / Completed
CompletedNCT00560820
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deferasirox | 30 mg/kg/day |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2007-11-20
- Last updated
- 2020-12-09
Locations
3 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00560820. Inclusion in this directory is not an endorsement.